UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Core Points - Aptorum Group Limited has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $1 per share [1] - The company has been granted a 180-calendar-day grace period until October 14, 2025, to regain compliance [2] - During this grace period, the company will evaluate options to restore compliance, including a potential reverse stock split [3] - Aptorum Group Limited is focused on the discovery, development, and commercialization of therapeutic assets for unmet medical needs [4]

Company Overview - Andean Precious Metals Corp. is a growing precious metals producer focused on expanding into top-tier jurisdictions in the Americas [2] - The company owns and operates the San Bartolomé processing facility in Potosí, Bolivia, and the Soledad Mountain mine in Kern County, California [2] - Andean is well-funded to act on future growth opportunities and aims to be a multi-asset, mid-tier precious metals producer [2] Leadership and Strategy - The leadership team is committed to creating value through safe, sustainable, and responsible operations [2] - The company has a strategic focus on operational excellence and community engagement, positioning itself for continued success and long-term growth [2] Market Activity - The company celebrated its graduation to the Toronto Stock Exchange, marking a significant milestone in its market presence [1]

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at an offering ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of ...

Exhibit 99.1 Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Apt ...

Clinical-stage biopharmaceutical firm Aptorum (NASDAQ:APM) is seeing its market value rise dramatically today on a merger between its wholly owned subsidiary and an artificial intelligence (AI) and automation platform. A combination of AI enthusiasm and some support from institutional investors is likely what’s helping APM stock rocket higher.Per MarketWatch, Aptorum has agreed to merge with YOOV Group, which specializes in leveraging advanced AI techniques to optimize business operations. Specifically, the ...

Aptorum (NASDAQ:APM) stock is rocketing higher on Wednesday after the biopharmaceutical company announced a merger agreement with YOOV Group.This will be a reverse merger that will see YOOV shareholders hold 90% of the combined company after the deal is complete. The remaining 10% will belong to current APM stockholders.To go along with this merger, Aptorum majority investor Jurchen Investment and wholly-owned subsidiary Aptorum Therapeutics Limited will take part in a split. That will see this legacy busin ...

NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”). The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of directors, the “Board”), respectively. If the Merger Agreement is approved by Aptorum’s and Y ...

Financial Performance - Revenue from healthcare services for the six months ended June 30, 2023, was $431,378, down 18% from $527,462 in the same period of 2022[7]. - Net loss attributable to Aptorum Group Limited increased to $5,487,104 for the six months ended June 30, 2023, compared to a net loss of $1,885,252 for the same period in 2022, reflecting a rise of approximately 191%[7]. - The company reported a net loss of $6,604,789 for the six months ended June 30, 2023, compared to a net loss of $2,729,788 for the same period in 2022, indicating a significant increase in losses[22]. - The company reported a net loss per share of $1.43 for the six months ended June 30, 2023, compared to a net loss per share of $0.53 for the same period in 2022[7]. - The basic and diluted loss per share for the six months ended June 30, 2023, was $(1.43), compared to $(0.53) for the same period in 2022[134]. Assets and Liabilities - Total current assets decreased from $7,067,802 as of December 31, 2022, to $1,897,991 as of June 30, 2023, representing a decline of approximately 73%[3]. - Total assets decreased from $20,867,371 as of December 31, 2022, to $14,412,041 as of June 30, 2023, a decline of about 31%[4]. - Total liabilities decreased from $13,034,066 as of December 31, 2022, to $1,632,564 as of June 30, 2023, a reduction of approximately 87%[4]. - As of June 30, 2023, total liabilities amounted to $1,044,028, a significant decrease of 83.1% from $6,166,807 as of December 31, 2022[71]. - The company’s accumulated deficit increased from $(65,337,075) as of December 31, 2022, to $(70,824,179) as of June 30, 2023, indicating a worsening financial position[4]. Cash Flow and Liquidity - Cash and cash equivalents decreased significantly from $1,882,545 as of December 31, 2022, to $340,306 as of June 30, 2023, a drop of approximately 82%[3]. - The company has approximately $2.3 million of unrestricted cash or cash equivalents and approximately $12 million of undrawn line of credit facility from a related party, indicating liquidity constraints[23]. - The company had a net cash used in operating activities of $6,193,088 for the six months ended June 30, 2023, compared to $6,913,290 for the same period in 2022, showing a slight improvement in cash flow management[17]. Operating Expenses - Total operating expenses decreased from $8,978,980 in the first half of 2022 to $6,970,226 in the first half of 2023, a reduction of approximately 22%[7]. - The company plans to maintain operating costs through strict cost control and budgeting to ensure sustainability over the next 12 months[24]. Impairment and Expenses - The company recognized an impairment loss on long-lived assets and inventories amounting to $767,505 during the reporting period[17]. - An impairment loss of $519,496 was recognized in research and development expenses for the six months ended June 30, 2023, related to various patented licenses[65]. - The Group recorded an impairment loss of $28,128 for office and medical equipment during the six months ended June 30, 2023[64]. - An impairment loss of $200,916 on right-of-use assets was recognized during the six months ended June 30, 2023[111]. Shareholder Actions - The Company issued 215,959 Class A Ordinary Shares at an average price of $7.53 per share, generating gross proceeds of $1.6 million from the ATM Offering[115]. - A 10 for 1 share consolidation was effectuated on January 23, 2023, resulting in the creation of an additional 8,018 Class A Ordinary Shares[116]. - The Company merged with Aptorum Group Cayman Limited, changing the par value of its Class A and Class B Ordinary Shares from USD 10 to USD 0.00001[117]. - For the six months ended June 30, 2023, the Group issued 1,250,000 Class A Ordinary Shares to convertible note holders upon conversion[118]. - The Group granted 403,820 new share options with an exercise price of $2.68 per share on March 31, 2023[124]. Future Outlook - The company may seek additional capital in the future to fund its continued operations, which could lead to further dilution for shareholders[24]. - The company has prepared its financial statements on a going concern basis, indicating management's belief in the ability to continue operations despite current losses[24].